Last reviewed · How we verify
Amoxicillin and clavulanate
Amoxicillin and Clavulanate Potassium is an antibacterial drug.
Amoxicillin and Clavulanate, marketed by GlaxoSmithKline, is a well-established antibacterial drug primarily indicated for lower respiratory tract infections. The drug's key strength lies in its combination of amoxicillin and clavulanate potassium, which enhances its efficacy against a broad spectrum of bacteria. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Amoxicillin and clavulanate |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Lower Respiratory Tract Infections
- Acute Bacterial Otitis Media
- Sinusitis
- Skin and Skin Structure Infections
- Urinary Tract Infections
Common side effects
- diarrhea/loose stools
- nausea
- skin rashes and urticaria
- vomiting
- vaginitis
Drug interactions
- probenecid
- oral anticoagulants
- allopurinol
- oral contraceptives
Key clinical trials
- Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. (PHASE3)
- Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Collaborative Urological Prosthetics Investigation Directive Research Group (EARLY_PHASE1)
- 'Propolis Versus Chlorhexidine Gluconate on Wound Healing After Third Molar Surgery: a Randomized Controlled Trial' (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin and clavulanate CI brief — competitive landscape report
- Amoxicillin and clavulanate updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI